logo
Share SHARE
FONT-SIZE Plus   Neg

Genmab Announces First Phase III Trial Of Daratumumab - Quick Facts

Denmark-based biotechnology company Genmab A/S (GNMSF.PK) said its partner, Janssen Biotech, Inc. would begin a Phase III study of daratumumab in relapsed or refractory multiple myeloma. The trial would compare daratumumab in combination with lenalidomide and dexamethasone to lenalidomide and dexamethasone alone.

Genmab's Chief Executive stated: "The daratumumab development program is progressing very well. We are extremely pleased to be able to announce that this study evaluating daratumumab in combination with a core multiple myeloma treatment regime will initiate patient recruitment in the coming months."

The Phase III trial would comprise nearly 500 patients with relapsed or refractory multiple myeloma. Patients would be randomized to receive either daratumumab combined with lenalidomide and dexamethasone, or lenalidomide and dexamethasone alone. The company said the study's primary endpoint is progression free survival.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Computer and printer maker Hewlett-Packard Co. said Thursday after the markets closed that its second quarter profit fell 21% from last year, hurt by lower revenue and costs related to the planned separation of the company. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast. Accounting software maker Intuit reported a plunge in third-quarter profit, hurt by impairment charges, even as results topped Wall Street estimates, driven by growth in small business segment amid a strong tax season. Struggling teen-apparel retailer Aeropostale Inc. (ARO), Thursday said its first-quarter loss narrowed from a year ago, driven largely by stronger margins even as revenues continued to plunge dropped. Nevertheless, the company lost almost one-fifth of its market value in after-hours trade, with the...
comments powered by Disqus
Follow RTT